In a report from GlobalData, it estimates the 2014 pharmaceutical sales for the Huntington’s Disease (HD) market at approximately $252.6m across the 7 Major Markets, encompassing the US, the five major European countries (5EU; France, Germany, Italy, Spain, and UK), and Japan. GlobalData expects this market to grow at a significant compound annual growth rate (CAGR) during the forecast period; with the 5EU market is anticipated to grow at the fastest rate. In 2024, it is expected that the US will be the biggest contributor to the HD market, representing approximately 77.0% of the total HD drug sales.

HD is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders. Approved treatments for HD across the 7MM are extremely limited, consisting of only two symptomatic treatments, tetrabenazine and tiapride, which are both approved for the treatment of HD-associated chorea. Other treatment options contributing to the HD market are off-label symptomatic drugs, many of which  are widely genericized throughout the 7MM.

During the 10-year forecast period (2014-2024), it is expected that four new HD treatments will launch in the US and EU markets, and two new treatments will be launched in Japan. GlobalData anticipates that by the end of the forecast period in 2024, there will be a significant change in the HD market leaders across the 7MM.

Teva’s SD-809 is anticipated to be the first drug to launch in the 7MM, and is currently in the pre-registration phase in the US. This drug is a symptomatic treatment with an identical mechanism of action (MOA) to the currently marketed tetrabenazine, but importantly has a more favorable safety profile. Teva’s pridopidine is a first-in-class D2 receptor stabilizer for HD, which is anticipated to be utilized for the symptomatic treatment of non-choreic motor symptoms in patients. Pridopidine is expected to be the second pipeline agent to launch in the 7MM.